Pace Pharmatech Private Limited - Due diligence report

A 360° intelligence report on Pace Pharmatech Private Limited: trust score, financial health, credit view, compliance, directors, growth and…

2001-12-04 Andheri West, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
PP Pace Pharmatech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Pace Pharmatech Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
86/100
Trust Score
Low Risk

Pace Pharmatech Private Limited is assessed as Low Risk with a Trust Score of 86/100. Pace Pharmatech Private Limited is an active private limited indian non-government company incorporated in 2001, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 19 Aug 2026 from the latest processed filings. Pace Pharmatech Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (2.04 cr) · 5 satisfied (3.81 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others6 48.0 cr
Dena Bank1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SAURABH SANJAY AGARWAL 01234567 Director 01/04/2018 6 yrs Approved
SHIVAM AJAY AGARWAL 01234567 Director 01/04/2018 6 yrs Approved
SANJAY AGARWAL OMPRAKASH 01234567 Director 01/04/2018 6 yrs Approved
AJAY OMPRAKASH AGARWAL 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Operating for 24+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
2 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 2.04 cr already registered.
  • Compliance record supports lending.
Investor view72/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
05 Jun 2025
Director appointed
SHIVAM AJAY AGARWAL (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
02 Dec 2024
Charge satisfied
Others
01 Oct 2024
Charge satisfied
Others
13 Sep 2024
Charge created
Others - 2.00 cr
06 May 2024
Charge satisfied
Others
17 Jul 2020
Charge created
Others - 25.00 Lakh
01 Jun 2020
Charge satisfied
Others
09 Jul 2019
Charge created
Others - 1.75 cr
06 Sep 2018
Director appointed
SAURABH SANJAY AGARWAL (Director)
31 Jan 2018
Charge created
Others - 70.00 Lakh
31 Oct 2017
Charge created
Others - 41.00 Lakh
15 Feb 2011
Securities allotted
235000.00 Equity Shares - 23.50 Lakh raised
05 Jul 2004
Director appointed
SANJAY AGARWAL OMPRAKASH (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ankar Industries Pvt Ltd U24211WB1974PTC029387 Kolkata, West Bengal, India
Glamic Hygiene Products Private Limited U24100DL2012PTC230082 Delhi, Delhi, India
Kalpana Chemicals Private Limited U24110TG1973PTC001611 Andhra Pradesh, Telangana, India
Sindhu Ultramarine Chemicals Private Limited U24299GJ1987PTC009772 Rajkot, Gujarat, India
Mahalaxmi Silicates Private Limited U17100HR2008PTC112466 Panipat, Haryana, India
Shri Meera Labs Private Limited U24297TN2007PTC062007 Chennai, Tamil Nadu, India
Aero Pack Products Private Limited U22219MH2007PTC171423 Navi Mumbai, Maharashtra, India
Ralph Agro Rasayan Private Limited U01403DL2008PTC183015 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Pace Pharmatech Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Pace Pharmatech Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Pace Pharmatech Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Pace Pharmatech Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Pace Pharmatech Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Pace Pharmatech Private Limited an active company?

Pace Pharmatech Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Pace Pharmatech Private Limited financially healthy?

Pace Pharmatech Private Limited has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Pace Pharmatech Private Limited?

Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Pace Pharmatech Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Pace Pharmatech Private Limited have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 5 earlier charge(s) stand satisfied.

Is Pace Pharmatech Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Pace Pharmatech Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.